Stock AnalizJohnson & Johnson JNJ
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Johnson & Johnson (JNJ) is a healthcare company listed in the US with a market value of about $687.9B. In the twelve months to September 27, 2026 it had revenue of $99.3B and net income of $16.1B, a net margin of 16.2%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is shareholder returns (5/5); the weakest is value (0/5).
Key numbers: a P/E of 43.4, a price to free cash flow of 33.4, 5-year revenue growth of 3% a year, a 5-year average ROIC of 17%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 39% below the current price.
Score: 2.6 / 5
Checks passed
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Positive free cash flow
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $99.3B | $94.2B | $88.8B | $85.2B | $80.0B | $78.7B | $82.6B | $82.1B | $81.6B | $76.5B | $71.9B |
| Net income | $16.1B | $26.8B | $14.1B | $35.2B | $17.9B | $20.9B | $14.7B | $15.1B | $15.3B | $1.3B | $16.5B |
| Free cash flow | $20.6B | $19.7B | $19.8B | $18.2B | $17.2B | $19.8B | $20.2B | $19.9B | $18.5B | $17.8B | $15.5B |
| EPS (diluted) | $6.59 | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 |
| Net margin | 16.2% | 28.5% | 15.8% | 41.3% | 22.4% | 26.5% | 17.8% | 18.4% | 18.8% | 1.7% | 23.0% |
| ROIC | — | 22.2% | 14.0% | 14.4% | 15.6% | 16.8% | 15.1% | 17.5% | 17.9% | 15.9% | 18.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 22 analysts is $279.41, 2% below the current price; targets range from $190.00 to $320.00; the consensus rating is “Buy”; expected EPS is $11.12 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Johnson & Johnson’s P/E ratio?
About 43.4, based on the last twelve months of diluted earnings per share (forward P/E about 25.1).
Is Johnson & Johnson stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 39% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Johnson & Johnson pay a dividend?
Yes. The dividend yield is about 1.91%, and it has paid dividends for 10 years in our data.
Is Johnson & Johnson a good stock to buy?
We do not give buy or sell advice. Johnson & Johnson scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.